CD274 and neoplasm: Neither the PD-L1 expression in tumour cells nor in immune cells correlated with better outcomes in patients treated with chemotherapy plus durvalumab [15] Similarly to the CASPIAN and IMPower133 trials, in the phase III study, Keynote 604, the addition of pembrolizumab to a platinum and etoposide regimen was shown to improve the PFS rate (12-month PFS, 13.6% versus 3.1%), and prolonged OS (24-month, 22.5% versus 11%), although the significance threshold was not reached for the OS rate.